Ajanta Pharma has partnered with Biocon to in-license semaglutide, a GLP-1 therapy for adult diabetes management. Biocon will supply the drug for marketing across select emerging markets. Ajanta aims to launch the product after patent expiry in March 2026 and regulatory clearances expected in late 2026 or early 2027.